US2011071612A1PendingUtilityA1

Anti-angiogenic compositions and methods of use

61
Assignee: ANGIOTECH PHARM INCPriority: Jul 19, 1993Filed: Jun 17, 2010Published: Mar 24, 2011
Est. expiryJul 19, 2013(expired)· nominal 20-yr term from priority
Inventors:William L. HunterLindsay MachanA. Arsenault
A61P 9/10A61P 35/00A61P 9/14A61P 43/00A61P 7/02A61P 7/04A61P 9/00A61P 27/02A61P 19/02A61P 11/00A61P 13/02A61P 1/04A61P 1/16A61L 31/145A61K 9/0019A61K 9/5146A61K 31/565C08L 2203/02A61K 9/5031A61K 9/0051A61L 2300/622C07C 233/64A61K 9/1647A61K 31/519A61L 2300/416A61L 2300/606A61L 2430/36A61K 31/427Y10S977/915A61K 33/00C08L 23/0853A61K 31/426A61K 31/136A61K 33/06C08L 29/04A61K 9/1641A61K 9/14A61K 31/335A61K 31/122A61K 31/57A61K 45/06C08L 2312/00A61K 31/185A61K 9/1635A61K 9/5153A61K 31/555A61K 38/57B82Y 5/00A61K 9/0048A61K 31/4745A61K 31/702A61K 31/203A61K 9/1658A61K 33/30A61L 31/10C08L 67/04A61K 9/7007A61K 31/165A61K 31/337A61K 31/525A61L 31/16Y10S977/773C07K 14/811A61K 31/20A61K 33/24
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

Claims

exact text as granted — not AI-modified
1 - 35 . (canceled) 
     
     
         36 . A vascular stent for delivering a compound to a site of an angioplasty in a blood vessel,
 wherein the vascular stent comprises   a composition capable of releasing the compound into a tissue surrounding the vascular stent, and wherein the composition comprises paclitaxel.   
     
     
         37 . The stent of  claim 36 , further comprising a polymeric carrier. 
     
     
         38 . The stent of  claim 37 , wherein the polymeric carrier comprises a biodegradable polymer. 
     
     
         39 . The stent of  claim 37 , wherein the polymeric carrier comprises poly(d,l-lactide-co-glycolide). 
     
     
         40 . The stent of any one of  claims 36 - 39 , wherein the stent is a coronary stent. 
     
     
         41 . A vascular stent for delivering a compound to a site of an angioplasty in a blood vessel,
 wherein the vascular stent comprises   a composition capable of releasing the compound into a tissue surrounding the vascular stent, and wherein the composition comprises paclitaxel or an analog thereof.   
     
     
         42 . The stent of  claim 41 , wherein the stent is a coronary stent. 
     
     
         43 . The stent of  claim 42 , further comprising a polymeric carrier. 
     
     
         44 . The stent of  claim 43 , wherein the polymeric carrier comprises a biodegradable polymer. 
     
     
         45 . A coronary stent, wherein the coronary stent comprises a polymer and paclitaxel. 
     
     
         46 . The coronary stent of  claim 45  wherein the stent is balloon expandable. 
     
     
         47 . The coronary stent of  claim 45  wherein the polymer is biodegradable. 
     
     
         48 . The coronary stent of  claim 45  wherein the polymer is poly(d,l-lactide-co-glycolide). 
     
     
         49 . A coronary stent comprising a polymer and paclitaxel or an analog thereof. 
     
     
         50 . The coronary stent of  claim 49  wherein the polymer is poly(d,l-lactide-co-glycolide). 
     
     
         51 . A stent comprising a generally tubular structure and a composition comprising paclitaxel, where the composition adheres to the structure during storage. 
     
     
         52 . The stent of  claim 51  wherein the composition comprises a biodegradable polymer. 
     
     
         53 . The stent of  claim 51  which is a coronary stent for preventing a narrowing of a coronary artery. 
     
     
         54 . In a stent, wherein the improvement comprises the stent comprising paclitaxel. 
     
     
         55 . The stent of  claim 54  wherein the stent further comprises a polymeric carrier. 
     
     
         56 . The stent of  claim 55  wherein the polymeric carrier is biodegradable. 
     
     
         57 . The stent of  claim 55  wherein the polymeric carrier comprises poly(d,l-lactide-co-glycolide). 
     
     
         58 . The stent of any one of  claims 54 - 57  wherein the stent is a vascular stent. 
     
     
         59 . In a stent, wherein the improvement comprises the stent comprising paclitaxel or an analog thereof, and a polymeric carrier. 
     
     
         60 . The stent of  claim 59  wherein the polymeric carrier is biodegradable. 
     
     
         61 . The stent of  claim 59  wherein the polymeric carrier is poly(d,l-lactide-co-glycolide). 
     
     
         62 . The stent of any one of  claims 59 - 61  wherein the stent is a vascular stent. 
     
     
         63 . A stent comprising a generally tubular structure coated with a composition comprising a polymeric carrier and paclitaxel. 
     
     
         64 . The stent of  claim 63  which is self-expanding. 
     
     
         65 . The stent of  claim 63  which is balloon expandable. 
     
     
         66 . The stent of  claim 63 , where the stent is a vascular stent.

Join the waitlist — get patent alerts

Track US2011071612A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.